


Chk1-IN-5

| | |
|---------------------------|---|
| Cat. No.: | HY-131446 |
| CAS No.: | 2120398-39-0 |
| Molecular Formula: | C ₁₈ H ₁₈ FN ₇ O ₂ |
| Molecular Weight: | 383.38 |
| Target: | Checkpoint Kinase (Chk) |
| Pathway: | Cell Cycle/DNA Damage |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | | | | | | | | | |
|-------------------------------------|---|---------------|---|---------|----------|-----------------|------------------------------|---------|-------------------------|---------------|---|---------|----------|-----------------|-------------------------------------|---------|---|
| Description | Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model ^[1] . | | | | | | | | | | | | | | | | |
| IC₅₀ & Target | Chk1 | | | | | | | | | | | | | | | | |
| In Vitro | Chk1-IN-5 (compound 3; 0.4, 1.2, 3.7, 11.1, 33.3, 100 nM) inhibits Chk1 phosphorylation in the HT-29 colon cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | | | | | | | | | | | | | | | |
| In Vivo | <p>Chk1-IN-5 (compound 3; 40 mg/kg; IV; twice a week for 21 days) inhibits tumor growth in Baib/c nude mice with HT-29 colon cancer cells^[1].</p> <p>Chk1-IN-5 (10 mg/kg; via tail vein intravenous injection) displays a longer half-life (T_{1/2}=3.8 hours) and higher exposure (CL=2.3 L/hr•kg; V_{ss}=6.4 L/kg; AUC=4531 ng/ml•h)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Baib/c nude mice with HT-29 colon cancer cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>40 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IV; twice a week for 21 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male SD rats (280-350 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Via tail vein intravenous injection</td> </tr> <tr> <td>Result:</td> <td>Displayed a longer half-life (T_{1/2}=3.8 hours) and higher exposure (CL=2.3 L/hr•kg; V_{ss}=6.4 L/kg; AUC=4531 ng/ml•h).</td> </tr> </table> | Animal Model: | Baib/c nude mice with HT-29 colon cancer cells ^[1] | Dosage: | 40 mg/kg | Administration: | IV; twice a week for 21 days | Result: | Inhibited tumor growth. | Animal Model: | Male SD rats (280-350 g) ^[1] | Dosage: | 10 mg/kg | Administration: | Via tail vein intravenous injection | Result: | Displayed a longer half-life (T _{1/2} =3.8 hours) and higher exposure (CL=2.3 L/hr•kg; V _{ss} =6.4 L/kg; AUC=4531 ng/ml•h). |
| Animal Model: | Baib/c nude mice with HT-29 colon cancer cells ^[1] | | | | | | | | | | | | | | | | |
| Dosage: | 40 mg/kg | | | | | | | | | | | | | | | | |
| Administration: | IV; twice a week for 21 days | | | | | | | | | | | | | | | | |
| Result: | Inhibited tumor growth. | | | | | | | | | | | | | | | | |
| Animal Model: | Male SD rats (280-350 g) ^[1] | | | | | | | | | | | | | | | | |
| Dosage: | 10 mg/kg | | | | | | | | | | | | | | | | |
| Administration: | Via tail vein intravenous injection | | | | | | | | | | | | | | | | |
| Result: | Displayed a longer half-life (T _{1/2} =3.8 hours) and higher exposure (CL=2.3 L/hr•kg; V _{ss} =6.4 L/kg; AUC=4531 ng/ml•h). | | | | | | | | | | | | | | | | |

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA